Full Press Release Details
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) --Molecular PartnersAG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences.
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ:
TD Cowen’s 6thAnnual Oncology Innovation Summit: Insights for ASCO & EHA:
Both events will be webcast and available on the Molecular Partnerswebsite,under the investors tab.
About Molecular Partners AGMolecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visitwww.molecularpartners.comand find us on LinkedIn and Twitter / X@MolecularPrtnrs
For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, U.S.seth.lewis@molecularpartners.comTel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & CommunicationsZurich-Schlieren, Switzerlandlaura.jeanbart@molecularpartners.comTel: +41 44 575 19 35